Evaluating anticancer properties of Withaferin A-a potent phytochemical
- PMID: 36339589
- PMCID: PMC9629854
- DOI: 10.3389/fphar.2022.975320
Evaluating anticancer properties of Withaferin A-a potent phytochemical
Abstract
Withaferin A is a C28 steroidal lactone derived from the plant Withania somnifera, commonly known as Ashwagandha. Withaferin A has received great attention for its anticancer properties noted in cancer cells of various origins. Extracts of Withania somnifera have been used in traditional Ayurvedic and Unani Indian medicine for their various pharmacological benefits. In recent years, Withania somnifera or Ashwagandha extract has become popularized as a health supplement marketed for its stress and anxiety reducing effects. Withaferin A is one of the most studied withanolides extracted from Withania somnifera that has gained great attention for its anticancer, anti-inflammatory, metabolic, and pro-apoptotic effects. Extensive in vivo and in vitro studies have depicted Withaferin A's interactions with key role players in cancerous activity of the cell to exert its pro-apoptotic effects. Withaferin A interactions with NF-κB, STAT, Hsp90, ER-α, p53, and TGF-β have noted inhibition in cancer cell proliferation and cell cycle arrest in G2/M stage, ultimately leading to apoptosis or cell death. This review highlights pro-apoptotic properties of Withaferin A including generation of reactive oxidative species, Par-4 activation, endoplasmic reticulum stress (ER) induction, and p53 activation. Analysis of Withaferin A's involvement in various oncogenic pathways leading to malignant neoplasm and its pharmacologic activity in conjunction with various cancer drugs provides promising evidence in therapeutic potential of Withaferin A as a cancer treatment.
Keywords: Ashwagandha; Withaferin A; Withania somnifera; apoptosis; cancer; cancer treatment; withanolides.
Copyright © 2022 Atteeq.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Abeesh P., Vishnu W. K., Guruvayoorappan C. (2021). Preparation and characterization of withaferin A loaded pegylated nanoliposomal formulation with high loading efficacy: In vitro and in vivo anti-tumour study. Mat. Sci. Eng. C Mat. Biol. Appl. 128, 112335. 10.1016/j.msec.2021.112335 - DOI - PubMed
-
- Ahmed W., Mofed D., Zekri A.-R., El-Sayed N., Rahouma M., Sabet S. (2018). Antioxidant activity and apoptotic induction as mechanisms of action of Withania somnifera (Ashwagandha) against a hepatocellular carcinoma cell line. J. Int. Med. Res. 46, 1358–1369. 10.1177/0300060517752022 - DOI - PMC - PubMed
-
- Alnuqaydan A. M., Almutary A., Bhat G. R., Mir T. A., Wani S. I., Rather M. Y., et al. (2022). Evaluation of the cytotoxic, anti-inflammatory, and immunomodulatory effects of Withaferin A (WA) against lipopolysaccharide (LPS)-induced inflammation in immune cells derived from BALB/c mice. Pharmaceutics 14, 1256. 10.3390/pharmaceutics14061256 - DOI - PMC - PubMed
-
- Aphale A. A., Chhibba A. D., Kumbhakarna N. R., Mateenuddin M., Dahat S. H. (1998). Subacute toxicity study of the combination of ginseng (Panax ginseng) and Ashwagandha (Withania somnifera) in rats: A safety assessment. Indian J. Physiol. Pharmacol. 42, 299–302. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
